99103-38-5

Basic information

• Product Name: Benzenamine, 3-nitro-4-(phenylmethoxy)-
• CAS NO: 99103-38-5
• Molecular Formula: C13H12N2O3
• Molecular Weight: 244.25
• Mol File: 99103-38-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenamine, 3-nitro-4-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 3-nitro-4-(phenylmethoxy)-(99103-38-5)
• EPA Substance Registry System: Benzenamine, 3-nitro-4-(phenylmethoxy)-(99103-38-5)

Safety Data

• Hazardous Substances Data: 99103-38-5(Hazardous Substances Data)

Upstream product

• 2734-78-3 1-(benzyloxy)-2,4-dinitrobenzene 
• 197442-80-1 2-nitro-4-(1,1-dimethylethoxycarbonylamino)phenol 
• 119-34-6 4-amino-2-nitrophenol 
• 1223466-35-0 4-benzyloxy-3-nitroacetanilide 
• 100-51-6 benzyl alcohol 
• 97-00-7 1-chloro-2,4-dinitro-benzene 

Relevant articles and documents

Synthesis and bioevaluation of 2-phenyl-5-methyl-2H-1,2,3-triazole-4-carboxylic acid/carbohydrazide derivatives as potent xanthine oxidase inhibitors

A series of 2-phenyl-5-methyl-2H-1,2,3-triazole-4-carboxylic acids/carbohydrazides as analogues of febuxostat were synthesized and evaluated for their in vitro xanthine oxidase (XO) inhibitory activity. Among these compounds, the carboxylic acid derivatives 7a-h and 8a-h exhibited high potency in the submicromolar/nanomolar range. Steady-state kinetics experiment revealed that 7f was a mixed-type inhibitor of xanthine oxidase. In addition, a molecular docking study of 7f was performed to determine its binding mode at the active site of xanthine oxidase.

PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furhtermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.